nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—SLC15A1—Lisinopril—systemic scleroderma	0.311	0.52	CbGbCtD
L-DOPA—SLC15A1—Captopril—systemic scleroderma	0.233	0.39	CbGbCtD
L-DOPA—CYP2D6—Captopril—systemic scleroderma	0.0538	0.0901	CbGbCtD
L-DOPA—Mimosine—CCL2—systemic scleroderma	0.0102	1	CrCbGaD
L-DOPA—SLC7A5—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.00775	0.829	CbGdCrCtD
L-DOPA—PSIP1—digestive system—systemic scleroderma	0.00124	0.109	CbGeAlD
L-DOPA—PSIP1—lung—systemic scleroderma	0.00104	0.0907	CbGeAlD
L-DOPA—SLC7A5—Desoximetasone—Mometasone—systemic scleroderma	0.00104	0.111	CbGdCrCtD
L-DOPA—SLC7A8—skin of body—systemic scleroderma	0.00102	0.0895	CbGeAlD
L-DOPA—SLC7A5—connective tissue—systemic scleroderma	0.00088	0.0768	CbGeAlD
L-DOPA—SLC7A5—smooth muscle tissue—systemic scleroderma	0.000805	0.0703	CbGeAlD
L-DOPA—SLC7A5—skin of body—systemic scleroderma	0.000794	0.0694	CbGeAlD
L-DOPA—SLC7A8—tendon—systemic scleroderma	0.00078	0.0681	CbGeAlD
L-DOPA—SLC7A8—lung—systemic scleroderma	0.000685	0.0598	CbGeAlD
L-DOPA—SLC7A5—digestive system—systemic scleroderma	0.000635	0.0555	CbGeAlD
L-DOPA—SLC7A5—tendon—systemic scleroderma	0.000605	0.0528	CbGeAlD
L-DOPA—DDC—lung—systemic scleroderma	0.000592	0.0517	CbGeAlD
L-DOPA—SLC7A5—Desoximetasone—Prednisone—systemic scleroderma	0.000565	0.0605	CbGdCrCtD
L-DOPA—SLC7A5—lung—systemic scleroderma	0.000531	0.0463	CbGeAlD
L-DOPA—SLC15A1—digestive system—systemic scleroderma	0.000527	0.0461	CbGeAlD
L-DOPA—SLC16A10—tendon—systemic scleroderma	0.000463	0.0404	CbGeAlD
L-DOPA—SLC16A10—lung—systemic scleroderma	0.000406	0.0355	CbGeAlD
L-DOPA—Back pain—Mycophenolate mofetil—systemic scleroderma	0.0004	0.00108	CcSEcCtD
L-DOPA—Dyspnoea—Leflunomide—systemic scleroderma	0.0004	0.00108	CcSEcCtD
L-DOPA—Hypotension—Mycophenolic acid—systemic scleroderma	0.0004	0.00108	CcSEcCtD
L-DOPA—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000398	0.00107	CcSEcCtD
L-DOPA—Discomfort—Lisinopril—systemic scleroderma	0.000397	0.00107	CcSEcCtD
L-DOPA—Dyspepsia—Leflunomide—systemic scleroderma	0.000395	0.00106	CcSEcCtD
L-DOPA—Vomiting—Mometasone—systemic scleroderma	0.000394	0.00106	CcSEcCtD
L-DOPA—Dry mouth—Lisinopril—systemic scleroderma	0.000393	0.00106	CcSEcCtD
L-DOPA—Sweating increased—Prednisone—systemic scleroderma	0.000392	0.00105	CcSEcCtD
L-DOPA—Feeling abnormal—Azathioprine—systemic scleroderma	0.000391	0.00105	CcSEcCtD
L-DOPA—Rash—Mometasone—systemic scleroderma	0.00039	0.00105	CcSEcCtD
L-DOPA—Asthenia—Captopril—systemic scleroderma	0.00039	0.00105	CcSEcCtD
L-DOPA—Dermatitis—Mometasone—systemic scleroderma	0.00039	0.00105	CcSEcCtD
L-DOPA—Decreased appetite—Leflunomide—systemic scleroderma	0.00039	0.00105	CcSEcCtD
L-DOPA—Confusional state—Lisinopril—systemic scleroderma	0.000388	0.00105	CcSEcCtD
L-DOPA—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000388	0.00104	CcSEcCtD
L-DOPA—Headache—Mometasone—systemic scleroderma	0.000388	0.00104	CcSEcCtD
L-DOPA—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000387	0.00104	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000387	0.00104	CcSEcCtD
L-DOPA—Insomnia—Mycophenolic acid—systemic scleroderma	0.000387	0.00104	CcSEcCtD
L-DOPA—Fatigue—Leflunomide—systemic scleroderma	0.000387	0.00104	CcSEcCtD
L-DOPA—Oedema—Lisinopril—systemic scleroderma	0.000385	0.00104	CcSEcCtD
L-DOPA—Pruritus—Captopril—systemic scleroderma	0.000385	0.00104	CcSEcCtD
L-DOPA—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000384	0.00103	CcSEcCtD
L-DOPA—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000384	0.00103	CcSEcCtD
L-DOPA—Pain—Leflunomide—systemic scleroderma	0.000383	0.00103	CcSEcCtD
L-DOPA—Constipation—Leflunomide—systemic scleroderma	0.000383	0.00103	CcSEcCtD
L-DOPA—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000382	0.00103	CcSEcCtD
L-DOPA—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000381	0.00103	CcSEcCtD
L-DOPA—Somnolence—Mycophenolic acid—systemic scleroderma	0.00038	0.00102	CcSEcCtD
L-DOPA—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00038	0.00102	CcSEcCtD
L-DOPA—Shock—Lisinopril—systemic scleroderma	0.000379	0.00102	CcSEcCtD
L-DOPA—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000378	0.00102	CcSEcCtD
L-DOPA—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000377	0.00101	CcSEcCtD
L-DOPA—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000376	0.00101	CcSEcCtD
L-DOPA—Abdominal pain—Azathioprine—systemic scleroderma	0.000375	0.00101	CcSEcCtD
L-DOPA—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000373	0.001	CcSEcCtD
L-DOPA—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000372	0.001	CcSEcCtD
L-DOPA—Diarrhoea—Captopril—systemic scleroderma	0.000372	0.001	CcSEcCtD
L-DOPA—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000372	0.001	CcSEcCtD
L-DOPA—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000371	0.000998	CcSEcCtD
L-DOPA—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00037	0.000996	CcSEcCtD
L-DOPA—Feeling abnormal—Leflunomide—systemic scleroderma	0.000369	0.000994	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000369	0.000994	CcSEcCtD
L-DOPA—Fatigue—Mycophenolic acid—systemic scleroderma	0.000369	0.000992	CcSEcCtD
L-DOPA—Nausea—Mometasone—systemic scleroderma	0.000368	0.00099	CcSEcCtD
L-DOPA—Anorexia—Lisinopril—systemic scleroderma	0.000367	0.000988	CcSEcCtD
L-DOPA—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000367	0.000986	CcSEcCtD
L-DOPA—Weight increased—Prednisone—systemic scleroderma	0.000366	0.000985	CcSEcCtD
L-DOPA—Ataxia—Methotrexate—systemic scleroderma	0.000366	0.000984	CcSEcCtD
L-DOPA—Pain—Mycophenolic acid—systemic scleroderma	0.000366	0.000984	CcSEcCtD
L-DOPA—Constipation—Mycophenolic acid—systemic scleroderma	0.000366	0.000984	CcSEcCtD
L-DOPA—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000365	0.000983	CcSEcCtD
L-DOPA—Weight decreased—Prednisone—systemic scleroderma	0.000364	0.000979	CcSEcCtD
L-DOPA—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000363	0.000978	CcSEcCtD
L-DOPA—Cough—Mycophenolate mofetil—systemic scleroderma	0.000361	0.000971	CcSEcCtD
L-DOPA—Hypotension—Lisinopril—systemic scleroderma	0.00036	0.000969	CcSEcCtD
L-DOPA—Dizziness—Captopril—systemic scleroderma	0.00036	0.000968	CcSEcCtD
L-DOPA—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000358	0.000964	CcSEcCtD
L-DOPA—Depression—Prednisone—systemic scleroderma	0.000358	0.000962	CcSEcCtD
L-DOPA—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000357	0.000961	CcSEcCtD
L-DOPA—Urticaria—Leflunomide—systemic scleroderma	0.000356	0.000958	CcSEcCtD
L-DOPA—Abdominal pain—Leflunomide—systemic scleroderma	0.000354	0.000954	CcSEcCtD
L-DOPA—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000354	0.000952	CcSEcCtD
L-DOPA—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000352	0.000948	CcSEcCtD
L-DOPA—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000352	0.000947	CcSEcCtD
L-DOPA—Myocardial infarction—Prednisone—systemic scleroderma	0.000352	0.000946	CcSEcCtD
L-DOPA—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000352	0.000946	CcSEcCtD
L-DOPA—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000351	0.000944	CcSEcCtD
L-DOPA—Hypersensitivity—Azathioprine—systemic scleroderma	0.00035	0.000941	CcSEcCtD
L-DOPA—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00035	0.000941	CcSEcCtD
L-DOPA—Insomnia—Lisinopril—systemic scleroderma	0.000348	0.000938	CcSEcCtD
L-DOPA—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000348	0.000936	CcSEcCtD
L-DOPA—Paraesthesia—Lisinopril—systemic scleroderma	0.000346	0.000931	CcSEcCtD
L-DOPA—Vomiting—Captopril—systemic scleroderma	0.000346	0.000931	CcSEcCtD
L-DOPA—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000344	0.000927	CcSEcCtD
L-DOPA—Dyspnoea—Lisinopril—systemic scleroderma	0.000343	0.000924	CcSEcCtD
L-DOPA—Rash—Captopril—systemic scleroderma	0.000343	0.000923	CcSEcCtD
L-DOPA—Dermatitis—Captopril—systemic scleroderma	0.000343	0.000922	CcSEcCtD
L-DOPA—Somnolence—Lisinopril—systemic scleroderma	0.000342	0.000921	CcSEcCtD
L-DOPA—Headache—Captopril—systemic scleroderma	0.000341	0.000917	CcSEcCtD
L-DOPA—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00034	0.000916	CcSEcCtD
L-DOPA—Dyspepsia—Lisinopril—systemic scleroderma	0.000339	0.000912	CcSEcCtD
L-DOPA—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000338	0.00091	CcSEcCtD
L-DOPA—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000338	0.000908	CcSEcCtD
L-DOPA—Decreased appetite—Lisinopril—systemic scleroderma	0.000335	0.000901	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000333	0.000895	CcSEcCtD
L-DOPA—Fatigue—Lisinopril—systemic scleroderma	0.000332	0.000894	CcSEcCtD
L-DOPA—Shock—Mycophenolate mofetil—systemic scleroderma	0.000332	0.000894	CcSEcCtD
L-DOPA—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.00033	0.000889	CcSEcCtD
L-DOPA—Hypersensitivity—Leflunomide—systemic scleroderma	0.00033	0.000889	CcSEcCtD
L-DOPA—Pain—Lisinopril—systemic scleroderma	0.000329	0.000886	CcSEcCtD
L-DOPA—Constipation—Lisinopril—systemic scleroderma	0.000329	0.000886	CcSEcCtD
L-DOPA—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000326	0.000878	CcSEcCtD
L-DOPA—Diarrhoea—Azathioprine—systemic scleroderma	0.000325	0.000874	CcSEcCtD
L-DOPA—Haemoglobin—Prednisone—systemic scleroderma	0.000324	0.000871	CcSEcCtD
L-DOPA—Nausea—Captopril—systemic scleroderma	0.000323	0.000869	CcSEcCtD
L-DOPA—Haemorrhage—Prednisone—systemic scleroderma	0.000322	0.000866	CcSEcCtD
L-DOPA—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000322	0.000866	CcSEcCtD
L-DOPA—Asthenia—Leflunomide—systemic scleroderma	0.000322	0.000865	CcSEcCtD
L-DOPA—Hallucination—Prednisone—systemic scleroderma	0.00032	0.000862	CcSEcCtD
L-DOPA—Feeling abnormal—Lisinopril—systemic scleroderma	0.000317	0.000854	CcSEcCtD
L-DOPA—Pruritus—Leflunomide—systemic scleroderma	0.000317	0.000853	CcSEcCtD
L-DOPA—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000315	0.000849	CcSEcCtD
L-DOPA—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000315	0.000848	CcSEcCtD
L-DOPA—Dizziness—Azathioprine—systemic scleroderma	0.000314	0.000845	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000312	0.000841	CcSEcCtD
L-DOPA—Asthenia—Mycophenolic acid—systemic scleroderma	0.000307	0.000826	CcSEcCtD
L-DOPA—Diarrhoea—Leflunomide—systemic scleroderma	0.000307	0.000825	CcSEcCtD
L-DOPA—Urticaria—Lisinopril—systemic scleroderma	0.000306	0.000823	CcSEcCtD
L-DOPA—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000305	0.000821	CcSEcCtD
L-DOPA—Abdominal pain—Lisinopril—systemic scleroderma	0.000305	0.000819	CcSEcCtD
L-DOPA—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000303	0.000815	CcSEcCtD
L-DOPA—Pruritus—Mycophenolic acid—systemic scleroderma	0.000303	0.000814	CcSEcCtD
L-DOPA—Vomiting—Azathioprine—systemic scleroderma	0.000302	0.000812	CcSEcCtD
L-DOPA—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000301	0.00081	CcSEcCtD
L-DOPA—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.0003	0.000807	CcSEcCtD
L-DOPA—Rash—Azathioprine—systemic scleroderma	0.000299	0.000805	CcSEcCtD
L-DOPA—Dermatitis—Azathioprine—systemic scleroderma	0.000299	0.000805	CcSEcCtD
L-DOPA—Depression—Methotrexate—systemic scleroderma	0.000299	0.000804	CcSEcCtD
L-DOPA—Flushing—Prednisone—systemic scleroderma	0.000299	0.000804	CcSEcCtD
L-DOPA—Headache—Azathioprine—systemic scleroderma	0.000297	0.0008	CcSEcCtD
L-DOPA—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000297	0.000799	CcSEcCtD
L-DOPA—Dizziness—Leflunomide—systemic scleroderma	0.000296	0.000798	CcSEcCtD
L-DOPA—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000293	0.000789	CcSEcCtD
L-DOPA—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000293	0.000787	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000291	0.000784	CcSEcCtD
L-DOPA—Pain—Mycophenolate mofetil—systemic scleroderma	0.000289	0.000777	CcSEcCtD
L-DOPA—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000289	0.000777	CcSEcCtD
L-DOPA—Arrhythmia—Prednisone—systemic scleroderma	0.000288	0.000774	CcSEcCtD
L-DOPA—Vomiting—Leflunomide—systemic scleroderma	0.000285	0.000767	CcSEcCtD
L-DOPA—Alopecia—Prednisone—systemic scleroderma	0.000285	0.000766	CcSEcCtD
L-DOPA—Hypersensitivity—Lisinopril—systemic scleroderma	0.000284	0.000764	CcSEcCtD
L-DOPA—Dizziness—Mycophenolic acid—systemic scleroderma	0.000283	0.000761	CcSEcCtD
L-DOPA—Rash—Leflunomide—systemic scleroderma	0.000283	0.000761	CcSEcCtD
L-DOPA—Dermatitis—Leflunomide—systemic scleroderma	0.000282	0.00076	CcSEcCtD
L-DOPA—Mental disorder—Prednisone—systemic scleroderma	0.000282	0.000759	CcSEcCtD
L-DOPA—Nausea—Azathioprine—systemic scleroderma	0.000282	0.000759	CcSEcCtD
L-DOPA—Headache—Leflunomide—systemic scleroderma	0.000281	0.000756	CcSEcCtD
L-DOPA—Agranulocytosis—Methotrexate—systemic scleroderma	0.00028	0.000753	CcSEcCtD
L-DOPA—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000278	0.000748	CcSEcCtD
L-DOPA—Asthenia—Lisinopril—systemic scleroderma	0.000276	0.000744	CcSEcCtD
L-DOPA—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000276	0.000743	CcSEcCtD
L-DOPA—Pruritus—Lisinopril—systemic scleroderma	0.000273	0.000733	CcSEcCtD
L-DOPA—Vomiting—Mycophenolic acid—systemic scleroderma	0.000272	0.000732	CcSEcCtD
L-DOPA—Haemoglobin—Methotrexate—systemic scleroderma	0.00027	0.000728	CcSEcCtD
L-DOPA—Rash—Mycophenolic acid—systemic scleroderma	0.00027	0.000726	CcSEcCtD
L-DOPA—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000269	0.000725	CcSEcCtD
L-DOPA—Haemorrhage—Methotrexate—systemic scleroderma	0.000269	0.000724	CcSEcCtD
L-DOPA—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000268	0.000721	CcSEcCtD
L-DOPA—Headache—Mycophenolic acid—systemic scleroderma	0.000268	0.000721	CcSEcCtD
L-DOPA—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000267	0.000718	CcSEcCtD
L-DOPA—Nausea—Leflunomide—systemic scleroderma	0.000266	0.000717	CcSEcCtD
L-DOPA—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000266	0.000715	CcSEcCtD
L-DOPA—Vision blurred—Prednisone—systemic scleroderma	0.000264	0.000711	CcSEcCtD
L-DOPA—Urethral disorder—Methotrexate—systemic scleroderma	0.000264	0.00071	CcSEcCtD
L-DOPA—Diarrhoea—Lisinopril—systemic scleroderma	0.000264	0.000709	CcSEcCtD
L-DOPA—Ill-defined disorder—Prednisone—systemic scleroderma	0.00026	0.0007	CcSEcCtD
L-DOPA—Anaemia—Prednisone—systemic scleroderma	0.000259	0.000697	CcSEcCtD
L-DOPA—Agitation—Prednisone—systemic scleroderma	0.000258	0.000693	CcSEcCtD
L-DOPA—DRD2—lung—systemic scleroderma	0.000257	0.0225	CbGeAlD
L-DOPA—Angioedema—Prednisone—systemic scleroderma	0.000256	0.000689	CcSEcCtD
L-DOPA—Dizziness—Lisinopril—systemic scleroderma	0.000255	0.000685	CcSEcCtD
L-DOPA—Nausea—Mycophenolic acid—systemic scleroderma	0.000254	0.000684	CcSEcCtD
L-DOPA—Malaise—Prednisone—systemic scleroderma	0.000253	0.00068	CcSEcCtD
L-DOPA—Syncope—Prednisone—systemic scleroderma	0.000251	0.000676	CcSEcCtD
L-DOPA—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000249	0.000669	CcSEcCtD
L-DOPA—Loss of consciousness—Prednisone—systemic scleroderma	0.000246	0.000663	CcSEcCtD
L-DOPA—Vomiting—Lisinopril—systemic scleroderma	0.000245	0.000659	CcSEcCtD
L-DOPA—Rash—Lisinopril—systemic scleroderma	0.000243	0.000654	CcSEcCtD
L-DOPA—Convulsion—Prednisone—systemic scleroderma	0.000243	0.000654	CcSEcCtD
L-DOPA—Dermatitis—Lisinopril—systemic scleroderma	0.000243	0.000653	CcSEcCtD
L-DOPA—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000242	0.000652	CcSEcCtD
L-DOPA—Hypertension—Prednisone—systemic scleroderma	0.000242	0.000651	CcSEcCtD
L-DOPA—Headache—Lisinopril—systemic scleroderma	0.000241	0.000649	CcSEcCtD
L-DOPA—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000239	0.000643	CcSEcCtD
L-DOPA—Anxiety—Prednisone—systemic scleroderma	0.000238	0.00064	CcSEcCtD
L-DOPA—Alopecia—Methotrexate—systemic scleroderma	0.000238	0.00064	CcSEcCtD
L-DOPA—Discomfort—Prednisone—systemic scleroderma	0.000236	0.000634	CcSEcCtD
L-DOPA—Mental disorder—Methotrexate—systemic scleroderma	0.000236	0.000634	CcSEcCtD
L-DOPA—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000231	0.000621	CcSEcCtD
L-DOPA—Dysgeusia—Methotrexate—systemic scleroderma	0.000229	0.000617	CcSEcCtD
L-DOPA—Nausea—Lisinopril—systemic scleroderma	0.000229	0.000616	CcSEcCtD
L-DOPA—Oedema—Prednisone—systemic scleroderma	0.000229	0.000616	CcSEcCtD
L-DOPA—Back pain—Methotrexate—systemic scleroderma	0.000227	0.00061	CcSEcCtD
L-DOPA—Shock—Prednisone—systemic scleroderma	0.000225	0.000606	CcSEcCtD
L-DOPA—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000223	0.000601	CcSEcCtD
L-DOPA—Hyperhidrosis—Prednisone—systemic scleroderma	0.000221	0.000595	CcSEcCtD
L-DOPA—Vision blurred—Methotrexate—systemic scleroderma	0.000221	0.000594	CcSEcCtD
L-DOPA—Anorexia—Prednisone—systemic scleroderma	0.000218	0.000587	CcSEcCtD
L-DOPA—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000217	0.000585	CcSEcCtD
L-DOPA—Anaemia—Methotrexate—systemic scleroderma	0.000217	0.000583	CcSEcCtD
L-DOPA—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000215	0.000577	CcSEcCtD
L-DOPA—Rash—Mycophenolate mofetil—systemic scleroderma	0.000213	0.000573	CcSEcCtD
L-DOPA—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000213	0.000572	CcSEcCtD
L-DOPA—Headache—Mycophenolate mofetil—systemic scleroderma	0.000211	0.000569	CcSEcCtD
L-DOPA—Malaise—Methotrexate—systemic scleroderma	0.000211	0.000568	CcSEcCtD
L-DOPA—Leukopenia—Methotrexate—systemic scleroderma	0.00021	0.000564	CcSEcCtD
L-DOPA—Insomnia—Prednisone—systemic scleroderma	0.000207	0.000557	CcSEcCtD
L-DOPA—Paraesthesia—Prednisone—systemic scleroderma	0.000205	0.000553	CcSEcCtD
L-DOPA—Cough—Methotrexate—systemic scleroderma	0.000204	0.00055	CcSEcCtD
L-DOPA—Convulsion—Methotrexate—systemic scleroderma	0.000203	0.000546	CcSEcCtD
L-DOPA—Dyspepsia—Prednisone—systemic scleroderma	0.000201	0.000542	CcSEcCtD
L-DOPA—Nausea—Mycophenolate mofetil—systemic scleroderma	0.0002	0.000539	CcSEcCtD
L-DOPA—Chest pain—Methotrexate—systemic scleroderma	0.000199	0.000537	CcSEcCtD
L-DOPA—Decreased appetite—Prednisone—systemic scleroderma	0.000199	0.000535	CcSEcCtD
L-DOPA—Fatigue—Prednisone—systemic scleroderma	0.000197	0.000531	CcSEcCtD
L-DOPA—Discomfort—Methotrexate—systemic scleroderma	0.000197	0.00053	CcSEcCtD
L-DOPA—Constipation—Prednisone—systemic scleroderma	0.000196	0.000526	CcSEcCtD
L-DOPA—Confusional state—Methotrexate—systemic scleroderma	0.000193	0.000519	CcSEcCtD
L-DOPA—Feeling abnormal—Prednisone—systemic scleroderma	0.000189	0.000507	CcSEcCtD
L-DOPA—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000187	0.000504	CcSEcCtD
L-DOPA—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000187	0.000503	CcSEcCtD
L-DOPA—CYP2D6—digestive system—systemic scleroderma	0.000185	0.0162	CbGeAlD
L-DOPA—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000185	0.000497	CcSEcCtD
L-DOPA—Anorexia—Methotrexate—systemic scleroderma	0.000182	0.00049	CcSEcCtD
L-DOPA—Urticaria—Prednisone—systemic scleroderma	0.000182	0.000489	CcSEcCtD
L-DOPA—Abdominal pain—Prednisone—systemic scleroderma	0.000181	0.000487	CcSEcCtD
L-DOPA—Hypotension—Methotrexate—systemic scleroderma	0.000179	0.000481	CcSEcCtD
L-DOPA—Insomnia—Methotrexate—systemic scleroderma	0.000173	0.000465	CcSEcCtD
L-DOPA—Paraesthesia—Methotrexate—systemic scleroderma	0.000172	0.000462	CcSEcCtD
L-DOPA—Dyspnoea—Methotrexate—systemic scleroderma	0.00017	0.000459	CcSEcCtD
L-DOPA—Somnolence—Methotrexate—systemic scleroderma	0.00017	0.000457	CcSEcCtD
L-DOPA—Hypersensitivity—Prednisone—systemic scleroderma	0.000169	0.000454	CcSEcCtD
L-DOPA—Dyspepsia—Methotrexate—systemic scleroderma	0.000168	0.000453	CcSEcCtD
L-DOPA—Decreased appetite—Methotrexate—systemic scleroderma	0.000166	0.000447	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000165	0.000444	CcSEcCtD
L-DOPA—Fatigue—Methotrexate—systemic scleroderma	0.000165	0.000444	CcSEcCtD
L-DOPA—Asthenia—Prednisone—systemic scleroderma	0.000164	0.000442	CcSEcCtD
L-DOPA—Pain—Methotrexate—systemic scleroderma	0.000164	0.00044	CcSEcCtD
L-DOPA—Pruritus—Prednisone—systemic scleroderma	0.000162	0.000436	CcSEcCtD
L-DOPA—Feeling abnormal—Methotrexate—systemic scleroderma	0.000158	0.000424	CcSEcCtD
L-DOPA—Diarrhoea—Prednisone—systemic scleroderma	0.000157	0.000421	CcSEcCtD
L-DOPA—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000156	0.000421	CcSEcCtD
L-DOPA—Urticaria—Methotrexate—systemic scleroderma	0.000152	0.000409	CcSEcCtD
L-DOPA—Dizziness—Prednisone—systemic scleroderma	0.000151	0.000407	CcSEcCtD
L-DOPA—Abdominal pain—Methotrexate—systemic scleroderma	0.000151	0.000407	CcSEcCtD
L-DOPA—Vomiting—Prednisone—systemic scleroderma	0.000145	0.000391	CcSEcCtD
L-DOPA—Rash—Prednisone—systemic scleroderma	0.000144	0.000388	CcSEcCtD
L-DOPA—Dermatitis—Prednisone—systemic scleroderma	0.000144	0.000388	CcSEcCtD
L-DOPA—Headache—Prednisone—systemic scleroderma	0.000143	0.000386	CcSEcCtD
L-DOPA—Hypersensitivity—Methotrexate—systemic scleroderma	0.000141	0.000379	CcSEcCtD
L-DOPA—Asthenia—Methotrexate—systemic scleroderma	0.000137	0.000369	CcSEcCtD
L-DOPA—Nausea—Prednisone—systemic scleroderma	0.000136	0.000366	CcSEcCtD
L-DOPA—Pruritus—Methotrexate—systemic scleroderma	0.000135	0.000364	CcSEcCtD
L-DOPA—Diarrhoea—Methotrexate—systemic scleroderma	0.000131	0.000352	CcSEcCtD
L-DOPA—Dizziness—Methotrexate—systemic scleroderma	0.000126	0.00034	CcSEcCtD
L-DOPA—Vomiting—Methotrexate—systemic scleroderma	0.000122	0.000327	CcSEcCtD
L-DOPA—Rash—Methotrexate—systemic scleroderma	0.000121	0.000324	CcSEcCtD
L-DOPA—Dermatitis—Methotrexate—systemic scleroderma	0.00012	0.000324	CcSEcCtD
L-DOPA—Headache—Methotrexate—systemic scleroderma	0.00012	0.000322	CcSEcCtD
L-DOPA—Nausea—Methotrexate—systemic scleroderma	0.000114	0.000306	CcSEcCtD
